Publication Name	World Journal of Cardiology
Manuscript ID	95713
Country	Sudan

Received	2024-04-16 18:12
Peer-Review Started	2024-04-16 18:12
To Make the First Decision
Return for Revision	2024-05-11 07:45
Revised	2024-05-20 18:19
Second Decision	2024-06-05 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-05 08:04
Articles in Press	2024-06-05 08:04
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-06-22 17:59
Typeset the Manuscript	2024-06-28 14:26
Publish the Manuscript Online	2024-07-24 13:09

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: Review of efficacy, safety, and outcomes
Manuscript Source	Unsolicited Manuscript
All Author List	Moiud Mohyeldin, Ahmed S Abuelgasim and Ahmed MG Mustafa
ORCID	Author(s) ORCID Number Moiud Mohyeldin http://orcid.org/0000-0002-5373-2163
Funding Agency and Grant Number
Corresponding Author	Moiud Mohyeldin, MD, Doctor, Doctor, Staff Physician, Department of Internal Medicine, University Of Medical Sciences and Technology, Ebed Khatim St, Khartoum 11111, Sudan. moiudahmed@gmail.com
Key Words	Peripheral artery disease; Proprotein convertase subtilisin/kexin type 9 inhibitors; Cardiovascular risk reduction; Evolocumab; Alirocumab; Lipid-lowering therapy; Major adverse limb events; Clinical outcomes; Cost-effectiveness; Safety profile
Core Tip	Evolocumab and alirocumab, which belong to the class of proprotein convertase subtilisin/kexin type 9 inhibitors, are effective in reducing cardiovascular events and major adverse limb events in peripheral artery disease patients. Despite their proven benefits, these inhibitors are underutilized in clinical practice, often due to providers’ lack of awareness and their concerns about cost. This highlights the need for further research to assess these inhibitors’ long-term effects and cost-effectiveness for specific patient groups.
Publish Date	2024-07-24 13:09
Citation	<p>Mohyeldin M, Abuelgasim AS, Mustafa AM. Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: Review of efficacy, safety, and outcomes. <i>World J Cardiol</i> 2024; 16(7): 397-401</p>
URL	https://www.wjgnet.com/1949-8462/full/v16/i7/397.htm
DOI	https://dx.doi.org/10.4330/wjc.v16.i7.397

Full Article (PDF)	WJC-16-397-with-cover.pdf
Manuscript File	95713-Review-FilipodiaCL.docx
Answering Reviewers	95713-answering-reviewers.pdf
Audio Core Tip	95713-audio.mp3
Conflict-of-Interest Disclosure Form	95713-conflict-of-interest-statement.pdf
Copyright License Agreement	95713-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	95713-non-native-speakers.pdf
Peer-review Report	95713-peer-reviews.pdf
Scientific Misconduct Check	95713-scientific-misconduct-check.jpg
Scientific Editor Work List	95713-scientific-editor-work-list.pdf
CrossCheck Report	95713-crosscheck-report.pdf